GW501516 - Dragon Pharma

Cardarine was developed by Ligand Pharmaceuticals in the 1990s to combat metabolic disorders like obesity and type 2 diabetes. It acts as a PPARD receptor agonist, promoting fatty acid oxidation and increasing endurance by shifting energy utilization from glucose to fats. Early studies showed significant improvements in lipid profiles and cardiovascular health, but its development was halted in 2009 after long-term animal studies indicated potential carcinogenic effects. Despite its discontinuation, Cardarine remains popular in athletic circles for its fat-burning and endurance-enhancing properties .

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about GW501516 by Dragon Pharma, consult with your doctor or healthcare professional.